Stabilizing the EGFR on the plasma membrane, NHERF1 increases cell sensitivity to the tyrosine kinase inhibitors that affect EGFR-driven motility and invadopodia-dependent ECM proteolysis in cancer cells [16]. Here, EGFR is linked to cancer.